Ann: Binding Term Sheet Signed with Ravi Krishnan, page-16

Reminds me of the early days of RAP. Except this has way less shares floated and will be generating solid income Q1 2018, with potential huge growth by the end of 2018. Using a P/E of 20 for a growth medical tech stock that will be generating transparent revenue is reasonable. If they make $10mill NPAT in the 2018 calendar year with a P/E of 20 then we are looking at a Market cap of $200 million. Multiples of the stock price from here. $2.2 approximately.

Are there only 78.5million shares floated?